Bowel Regimen Recommendations
For Patients With a Functioning Gastrointestinal Tract
Pharmacologic Classes
- Miralax – Osmotic laxative
- Sennokot – Stimulant laxative
- Milk of Magnesia – Osmotic laxative
- Bisacodyl Suppository – Stimulant laxative
- Lactulose – Osmotic laxative
Initial Regimen (At Admission)
- Start:
- Sennokot 2 tablets BID
- Miralax 17 g daily
Escalation Based on Time Without Bowel Movement
After 48 Hours
- Normal Renal Function:
-
Add Milk of Magnesia 15 mL PO TID
-
Impaired Renal Function:
- Add Lactulose 20 g PO TID
After 72 Hours
- Normal Renal Function:
- Increase Milk of Magnesia to 30 mL PO TID
-
Add Bisacodyl Suppository 10 mg PR ×1
-
Impaired Renal Function:
- Add Bisacodyl Suppository 10 mg PR ×1
After 96 Hours
- Add SMOG Enema 120 mL PR ×1
- Consider abdominal imaging (KUB)
Monitoring: Red Flags for Ileus or Obstruction
If constipation is accompanied by any of the following symptoms, obtain a KUB to assess for ileus or obstruction:
- Abdominal distention, discomfort, or firmness
- Decreased or absent flatus
- Increased belching or hiccups
- Nausea or vomiting
Bowel Regimen for Non-Functioning Gastrointestinal Tract
Use this section if an ileus is present on clinical exam or imaging.
Initial Management
- Place NG tube to low wall suction
- Make patient NPO
- Initiate IV fluids
- Monitor electrolytes as needed
- Continue per rectal bowel regimen
- Encourage ambulation (if appropriate)
- Repeat KUB PRN to monitor gas pattern
- Discontinue or minimize:
- Opioids
- Anticholinergics
- Dopamine agonists
- Anti-serotonergics
Advanced Pharmacologic Interventions
Ogilvie’s Syndrome (Confirmed on Imaging)
- Neostigmine
- Can only be given on 10N
- Use caution in patients with anastomosis
Postoperative Ileus or Opioid-Induced Constipation
Oral Naloxone
- Initial dose: 2 mg PO TID
- Max dose: 4 mg PO TID
- Max duration: 48 hours
- Monitor for opioid reversal, especially in liver disease
Methylnaltrexone
- Dose: 12 mg SQ ×1
- May repeat after 24 hours if no resolution
- Use only if:
- Imaging confirms no obstruction
- Oral naloxone has failed
- Must discuss with attending before ordering
- Use caution in patients with an anastomosis
Management of Diarrhea
Initial Steps
- Stop all bowel regimen agents
- Monitor electrolytes
If C. difficile Negative
- Imodium: 4 mg q6h PRN
-
Fiber supplementation:
-
Without feeding tube:
- Psyllium: 2 caps daily (max 5 caps QID)
-
With feeding tube:
- Nutrisource Fiber: 1 packet daily (max 6 packets/day; order under tube feeds)
-
Titrate dose and frequency as needed
References
- Yang A, Lam T, Jierjian E, et al. An Evaluation of docusate monotherapy and the prevention of opioid-induced constipation after surgery. J Pain Palliat Care Pharmacother. 2022; 36(1):18–23.
- Gathers K, Fawad K, Petros K. Evaluation of methylnaltrexone bromide for the treatment of postoperative ileus. Crit Care Med. 2013;41(12):929.
- Chamie K, Golla V, Lenis AT, et al. Peripherally Acting μ-Opioid Receptor Antagonists in the Management of Postoperative Ileus: a Clinical Review. J Gastrointest Surg. 2020. https://doi.org/10.1007/s11605-020-04671-x
- Valle RG, Godoy FL. Neostigmine for acute colonic pseudo-obstruction: a meta-analysis. Ann Med Surg (Lond). 2014;3(3):60–64.
- Dudi-Venkata NN, Kroon HM, Bedrikovetski S, et al. Impact of STIMUlant and osmotic LAXatives (STIMULAX trial) on gastrointestinal recovery after colorectal surgery: randomized clinical trial. Br J Surg. 2021 Jul 23;108(7):797–803.
- Beavers J, Orton L, Atchison L, et al. The Efficacy and Safety of Methylnaltrexone for the Treatment of Postoperative Ileus. Am Surg. 2022; 88(3):409–413.
- Gibson CM, Pass SE. Enteral naloxone for the treatment of opioid-induced constipation in the medical intensive care unit. J Crit Care. 2014; 29(5):803–807.
- Merchan C, Altshuler D, Papadopoulos J. Methylnaltrexone Versus Naloxone for Opioid-Induced Constipation in the Medical Intensive Care Unit. Ann Pharmacother. 51(3):203–208.
- Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage. 2002; 23(1):48–553.
Reviewed November 2024 By
- Caroline Banes, DNP, APRN, ACNP-BC
- Jennifer Beavers, PharmD, BCPS
- Jennifer Emerson, PharmD
- Bethany Evans, MSN, ACNP-BC
- Chelsea Tasaka, PharmD, BCCCP
- Caroline Jackson, PharmD